Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

IBIO
iBio, Inc. Common Stock
stock NASDAQ

At Close
Sep 3, 2026 3:59:55 PM EDT
1.30USD-0.763%(-0.01)354,195
0.00Bid   0.00Ask   0.00Spread
Pre-market
Sep 3, 2026 8:55:30 AM EDT
1.33USD+1.527%(+0.02)800
After-hours
Sep 3, 2026 4:39:30 PM EDT
1.30USD0.000%(0.00)2,351
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
11:21AM EST  iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease   Benzinga
09:00AM EST  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, today shared an update on its lead COVID-19 vaccine program, IBIO-202.   GlobeNewswire Inc
Jan 4, 2022
04:30PM EST  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System, today announced that it will participate in the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.   GlobeNewswire Inc
Dec 22, 2021
09:25AM EST  iBio, Inc.(NYSEA:IBIO) (iBio or the Company),a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-basedFastPharmingManufacturing System,todayannounced that it has adjourned its 2021 Annual Meeting of Shareholders (the Annual Meeting) with respect to Proposals 4 and 5.   GlobeNewswire Inc
Dec 21, 2021
09:20AM EST  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-basedFastPharmingManufacturing System, provides the following link to listen virtually to the 2021 Annual Shareholders meeting: www.virtualshareholdermeeting.com/IBIO2021. The meeting will be held at 9:00 AM EST on December 22, 2021.   GlobeNewswire Inc
Dec 10, 2021
08:30AM EST  -Shareholders Presently Supporting Reverse Split and Authorized Share Proposals by a 2-to-1 Margin -   GlobeNewswire Inc
Nov 30, 2021
04:03PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021   Benzinga
08:00AM EST  - iBios Board Urges Shareholders to Vote Today to Support Companys Strategic Growth Plans -   GlobeNewswire Inc
Nov 29, 2021
08:45AM EST  - Global Reliance on Spike Protein-Based Vaccines May Create Public Health Risks -   GlobeNewswire Inc
07:34AM EST  JMP Securities Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $1.5   Benzinga
Nov 26, 2021
07:08AM EST  The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).   RTTNews
Nov 17, 2021
04:33PM EST  Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote "FOR" All Proposals Ahead Of Annual Meeting   Benzinga
04:30PM EST  Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends   GlobeNewswire Inc
Nov 15, 2021
06:17PM EST  iBio Q1 EPS $(0.04) Up From $(0.05) YoY, Sales $211.00K Miss $491.00K Estimate   Benzinga
01:01PM EST  iBio Announces Collaboration With UT Southwestern To Investigate IBIO-100 In Solid Tumors   Benzinga
01:00PM EST  iBio Announces Collaboration with UT Southwestern to Investigate   GlobeNewswire Inc
11:07AM EST  Earnings Scheduled For November 15, 2021   Benzinga
Nov 3, 2021
07:06PM EDT  iBio Reports Purchase Of FastPharming Manufacturing Facility For $28.75M   Benzinga
Oct 26, 2021
08:35AM EDT  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System, today urged its stockholders to vote FOR all proposals put forth in the proxy statement prior to the Companys December 9, 2021 Annual Meeting of Stockholders.   GlobeNewswire Inc
Oct 14, 2021
06:12AM EDT  The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.00 A.M. EDT).   RTTNews
Sep 27, 2021
08:19AM EDT  IBio Reports Profit In Q4 - Quick Facts   RTTNews
07:59AM EDT  IBio FY Loss Per Share $0.12 Vs Loss $0.61 Last Year   RTTNews
07:33AM EDT  iBio FY21 EPS $(0.12) Up From $(0.61) YoY, Sales $2.37M Up From $1.64M YoY   Benzinga
07:30AM EDT  Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors   GlobeNewswire Inc
05:01AM EDT  Earnings Scheduled For September 27, 2021   Benzinga
Sep 20, 2021
04:32PM EDT  iBio To Participate In Cantor Virtual Global Healthcare Conference Monday, Sept. 27, 2021 At 10 a.m. EDT   Benzinga
04:30PM EDT  iBio to Participate in the Cantor 2021 Virtual Global Healthcare   GlobeNewswire Inc
07:30AM EDT  iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial   GlobeNewswire Inc
Sep 7, 2021
04:30PM EDT  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System, today announced that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, to be held virtually September 13-15, 2021.   GlobeNewswire Inc
Aug 26, 2021
07:24AM EDT  IBio Appoints William Clark To Board   RTTNews
07:00AM EDT  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, announced today the appointment of William D. (Chip) Clark to its Board of Directors, effective immediately.   GlobeNewswire Inc
Aug 25, 2021
11:16AM EDT  iBio Expands Immuno-Oncology Pipeline With RubrYc Deal   Benzinga
07:32AM EDT  iBio Announces Co. Has Signed A Definitive Worldwide Exclusive License Agreement With RubrYc Therapeutics For RTX-003, An Immunotherapy Candidate Targeting Regulatory T Cells; iBio Made An Upfront $5M Payment To RubrYc, With An Additional $2.5M Commitment For December 2021   Benzinga
07:32AM EDT  iBio Announces Co. Has Signed A Definitive Worldwide Exclusive License Agreement With RubrYc Therapeutics For RTX-003, An Immunotherapy Candidate Targeting Regulatory T Cells; iBio Made An Upfront $5M Payment To RubrYc, With An Additional $2.5M Commitment   Benzinga
07:30AM EDT  iBio Expands Immuno-Oncology Pipeline in AI Partnership with   GlobeNewswire Inc
Jul 15, 2021
05:10PM EDT  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (N protein) of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response.   GlobeNewswire Inc
Jul 9, 2021
06:10AM EDT  IBio Stock Ticks Higher After Adding Three Cancer Antibody Programs   Benzinga
Jul 8, 2021
04:17PM EDT  iBio Establishes Oncology Drug Discovery Pipeline with Three New   GlobeNewswire Inc
04:15PM EDT  iBio Says Establishes Oncology Drug Discovery Pipeline With 3 New Antibody Programs   Benzinga
Jun 9, 2021
04:30PM EDT  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, announced today the appointment of Evert (Eef) Schimmelpennink to its Board of Directors, effective immediately.   GlobeNewswire Inc
May 19, 2021
04:30PM EDT  iBio, Inc. (NYSE:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, announced today that management will present an update on the Companys business at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 4:00 p.m Eastern Time.   GlobeNewswire Inc
May 17, 2021
10:21AM EDT  IBio shares were trading higher after the company reported Q3 earnings results.   Benzinga
07:25AM EDT  iBio Q3 EPS $(0.04), Sales $765.00K Miss $800.00K Estimate   Benzinga
07:00AM EDT  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended March 31, 2021.   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For May 17, 2021   Benzinga
May 10, 2021
08:15AM EDT  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 third quarter financial results before market open on Monday, May 17, 2021. iBio management will host a webcast and conference call at 8:00 a.m. Eastern Time to discuss the results and provide a corporate update.   GlobeNewswire Inc
May 7, 2021
10:21AM EDT  Mid-Morning Market Update: Markets Open Higher; US Adds Only 266,000 Jobs In April   Benzinga
07:01AM EDT  iBio Stock Is Trading Higher After Announcing Next-Gen COVID-19 Vaccine Candidate   Benzinga
May 6, 2021
05:27PM EDT  iBio Reports Successful COVID-19 Vaccine Toxicology Study Results And Announced The Next-Gen COVID-19 Vaccine Program   Benzinga
May 4, 2021
05:18PM EDT  iBio Says Co, Fraunhofer USA Conclude Litigation, Enter License Agreement   Benzinga
Mar 9, 2021
04:30PM EST  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced that it will participate in the 33rd Annual Roth Conference, which will be held virtually from March 15-17, 2021.   GlobeNewswire Inc
Feb 16, 2021
04:14PM EST  iBio Q2 EPS $(0.04), Inline, Sales $705.00K Beat $500.00K Estimate   Benzinga
04:05PM EST  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended December 31, 2020.   GlobeNewswire Inc
08:29AM EST  iBio Appoints Robert M. Lutz as Chief Financial & Business Officer   Benzinga
08:00AM EST  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Robert M. Lutz as its Chief Financial & Business Officer (CFBO), effective March 4, 2021.   GlobeNewswire Inc
06:49AM EST  Earnings Scheduled For February 16, 2021   Benzinga
Feb 9, 2021
04:30PM EST  iBio to Report Fiscal 2021 Second Quarter Financial Results and   GlobeNewswire Inc
Jan 22, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 22, 2021   Benzinga
06:02AM EST  Cantor Fitzgerald Initiates Coverage On iBio with Overweight Rating, Announces Price Target of $3   Benzinga
Dec 28, 2020
07:35AM EST  IBio Appoints Martin Brenner As Its Chief Scientific Officer   RTTNews
07:30AM EST  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (CSO), effective January 18, 2020.   GlobeNewswire Inc
Dec 10, 2020
04:30PM EST  iBio Announces Closing of its Public Offering of Common Stock   GlobeNewswire Inc
Dec 8, 2020
02:31PM EST  Mid-Afternoon Market Update: Dow Jumps 150 Points; Stitch Fix Shares Gain On Upbeat Q1 Earnings   Benzinga
10:04AM EST  'IBIO don't buy the vaccine dream' -Research Report From Short Research Firm, Mariner Research   Benzinga
08:58AM EST  UPDATE: iBio Offering Price, Based On Number Of Shares And Gross Proceeds, Equates To ~$1.18/Share   Benzinga
08:55AM EST  iBio Prices 29.7M Share Offering For $35M In Gross Proceeds   Benzinga
08:55AM EST  iBio Announces Pricing of $35 Million Public Offering of Common Stock   GlobeNewswire Inc
Dec 7, 2020
04:02PM EST  iBio Announces A Common Stock Offering; No Size Disclosed   Benzinga
04:01PM EST  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced an underwritten public offering of its common stock. In addition, iBio has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.   GlobeNewswire Inc
08:44AM EST  iBio Says Received Executed Copy Of Second Amendment To License Agreement Between Co And University Of Pittsburgh   Benzinga
Dec 1, 2020
04:30PM EST  iBio Selected To Produce ATB Therapeutics' Bioengineered Antibody-Toxin Fusion Proteins   Benzinga
04:30PM EST  iBio Selected to Produce ATB Therapeutics   GlobeNewswire Inc
Nov 24, 2020
07:34AM EST  iBio Announces Issuance Of US Patent Covering Endostatin Peptides For Treating Fibrosis   Benzinga
07:30AM EST  iBio Announces Issuance of U.S. Patent Covering Endostatin   GlobeNewswire Inc
Nov 16, 2020
04:16PM EST  iBio Q1 EPS $(0.05), Up From $(0.21) YoY   Benzinga
04:05PM EST  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended September 30, 2020.   GlobeNewswire Inc
01:11PM EST  Yahoo Finance Trending Stocks For Monday, Nov. 16, 2020: MRNA, WMT, SPCE, BA, PFE, JD, ATHE, TSM, BNTX, TGT, NVAX, HDS, INO, IBIO, XOM, MU, PANW, HPR, TSN, CCL, CAN, GP, BBVA, MMEDF, WWR, UBER, O, RCL, RAPT   Benzinga
Nov 12, 2020
08:00AM EST  iBio, Inc.(NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced that management will participate in Alliance Global Partners Virtual Healthcare Symposium on November 19, 2020.   GlobeNewswire Inc
Nov 3, 2020
07:49AM EST  IBio Appoints Randy Maddux As COO   RTTNews
07:36AM EST  iBio Announces Appointment Of Randy J. Maddux As Chief Operating Officer   Benzinga
07:30AM EST  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Randy J. Maddux as its Chief Operating Officer (COO), effective December 1, 2020.   GlobeNewswire Inc
Oct 15, 2020
04:30PM EDT  10 Stocks Moving In Tuesday's After-Hours Session   Benzinga
04:05PM EDT  -Adds More Than 25 Years of Financial Leadership in Pharma/Biotech to the Team-   GlobeNewswire Inc
07:45AM EDT  IBio Appoints Alexandra Kropotova To Its Board   RTTNews
07:30AM EDT  - Senior Biopharm Executive with 20 Years of Immuno-Inflammatory Disease Therapeutic Experience -   GlobeNewswire Inc
Oct 14, 2020
04:10PM EDT  IBio Appoints Linda Armstrong To Board Of Directors   RTTNews
04:05PM EDT  - Accomplished Biopharm Exec with Years of Clinical Experience in Respiratory Diseases -   GlobeNewswire Inc
Oct 13, 2020
05:21PM EDT  10 Stocks Moving In Tuesday's After-Hours Session   Benzinga
04:07PM EDT  iBio FY20 EPS $(0.61) vs $(0.94) In FY19, Sales ~$1.6M vs $2M In FY19   Benzinga
04:05PM EDT  iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal year ended June 30, 2020, which included record revenues of over $1.1 million in the fiscal fourth quarter.   GlobeNewswire Inc
Oct 5, 2020
07:42AM EDT  IBio Regains Compliance With NYSE American Continued Listing Standards   RTTNews
Oct 2, 2020
07:01AM EDT  iBio Enters Into Agreement With Safi Biosolutions To Develop Growth Factors And Cytokines Using FastPharming System; iBio Has Agreed To Invest $1.5M In Safi In The Form Of A Convertible Promissory Note   Benzinga
07:00AM EDT  iBio Enters into Agreement with Safi Biosolutions to Develop   GlobeNewswire Inc
Sep 9, 2020
09:59AM EDT  iBio, Inc. (IBIO) said the company has selected IBIO-201, its LicKM-ubunit vaccine, as leading candidate for the prevention of SARS-CoV-2 infection. The company plans to engage additional collaborators for further characterization and testing of IBIO-201 prior to performing GLP toxicology studies.   RTTNews
09:18AM EDT  IBio Selects IBIO-201 As Leading Candidate For Prevention Of SARS-CoV-2 Infection   RTTNews
08:46AM EDT  iBio To Advance Coronavirus LicKM-Subunit Vaccine Candidate, IBIO-201   Benzinga
08:45AM EDT  IBIO-201 Produced Anti-Spike Neutralizing Antibodies in Pre-Clinical Studies   GlobeNewswire Inc
Aug 28, 2020
07:16AM EDT  iBio And Planet Biotechnology Enter Into Exclusive Worldwide License Agreement For Development Of A COVID-19 Therapeutic   Benzinga
Aug 25, 2020
11:59AM EDT  Mid-Morning Market Update: Markets Mostly Lower; Hormel Foods Earnings Top Views   Benzinga
Aug 10, 2020
03:11PM EDT  IBio shares are trading higher after the company provided an update on its Covid-19 vaccine program. Within the update, the company noted anti-SARS-CoV-2 spike titers to IBIO-201 were observed 21 days after immunization.   Benzinga
07:56AM EDT  iBio Inc. (IBIO) on Monday provided an update on one of its proprietary vaccine candidates being designed to prevent infection from the SARS-CoV-2 virus. The company noted that IBIO-201 demonstrated the ability to elicit anti-SARS-CoV-2 immune response in pre-clinical studies.   RTTNews
07:42AM EDT  IBio: IBIO-201 Shows Ability To Elicit Anti-SARS-CoV-2 Immune Response In Preclinical Studies   RTTNews
07:21AM EDT  iBio Says 'Early functional testing of mouse antisera from IBIO-201 immunized mice demonstrates the presence of antibodies that interfere with the binding of SARS-CoV-2 spike protein sequences to human ACE2 in ex vivo assays'   Benzinga
07:20AM EDT  iBio Provides Update On COVID-19 Vaccine Program; Says 10 District Preclinical Study Arms Have Been Concluded, Anti-SARS-CoV-2 Spike Titers To IBIO-201 Were Observed 21 Days After Immunization   Benzinga
07:15AM EDT  iBio Provides Update on IBIO-201 COVID-19 Vaccine Program   GlobeNewswire Inc
Jul 31, 2020
12:50PM EDT  iBio Shares Spike Higher; Seeing Co. CEO Estimates Co. Will Be ABle To Produce 200M-700M Doses of Coronavirus Vaccine   Benzinga
11:02AM EDT  Cramer Shares His Thoughts On Blink Charging, Dynatrace And More   Benzinga
Jul 21, 2020
10:53AM EDT  iBio shares are continuing higher after the stock rose almost 75% Monday on no apparent news.UPDATE: Shares have since reversed, now lower.   Benzinga
Jul 20, 2020
10:12AM EDT  Mid-Morning Market Update: Markets Mixed; Halliburton Profit Beats Views   Benzinga
10:01AM EDT  Morning Market Stats in 5 Minutes   Benzinga
05:11AM EDT  80 Biggest Movers From Friday   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC